HAVCR2 and glioma: Hence, the correlation between TrMRS and expression of immunotherapy targets suggested that gliomas with high TrMRS would express more immunotherapy targets and have better response to immunotherapy, such as PD-1/PD-L1 inhibitors and TIM3 inhibitors.